Contract ServicesBaxter is a parenteral market leader providing a range of proven contract services from process development of biopharmaceutical active ingredients to form–fill–finish of drug product into syringes, vials, and cartridges. Baxter offers the advantage of providing cytotoxic contract services from chemical synthesis (API) to scale-up for commercial production. With over fifteen years of experience, we provide contract development and manufacturing services for antibodies and protein therapeutics. Our licensed facilities in Hayward and Thousand Oaks, California, have capacity for pre-clinical to commercial scale production.
Baxter's Bloomington facility has expanded capacities for syringe and vial filling–finishing; and has added new capability in cartridge filling–finishing as well as a fully automated kitting line. Lyophilization capacity has increased along with the establishment of the Lyophilization Center of Excellence. Baxter can also provide analytical and microbiological services as well as validation and regulatory assistance.
Proprietary Formulation Technologies
NANOEDGE dispersion technology offers innovative formulations for your solubility challenges and is applicable to multiple routes of administration. It reduces the particle size of most drugs to nanometer size, which can enhance a drug's saturation solubility and dissolution rate. It also eliminates the need for undesirable cosolvents and can offer higher drug loading and subsequent lower dose volume.
The PROMAXX microsphere technology is a unique, elegant, and cost effective formulation platform, tailored to fit your specific requirements. It is applicable to a broad range of molecules — from small molecules and nucleic acids to peptides and proteins. PROMAXX technology can offer high drug loading and precise particle-size control and enable dosing flexibility across various administration routes such as injectable and pulmonary with various drug release profiles such as immediate- and sustained-release.
Corporate Relationships Sought
Baxter is actively pursuing and strengthening partnerships including co-development opportunities, out-licensing of internally developed products, and strategic or full-development programs.
NUMBER OF EMPLOYEES: